Biases in identifying risk factor thresholds: A new look at the "lower- is-better" controversy for cholesterol, blood pressure and other risk factors Ian.

Slides:



Advertisements
Similar presentations
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
Observational Studies and RCT Libby Brewin. What are the 3 types of observational studies? Cross-sectional studies Case-control Cohort.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Summarising findings about the likely impacts of options Judgements about the quality of evidence Preparing summary of findings tables Plain language summaries.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Critical Appraisal for MRCGP Jim McMorran Coventry GP GP trainer Editor GPnotebook (
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Analytic Epidemiology
INTRODUCTION TO EPIDEMIOLO FOR POME 105. Lesson 3: R H THEKISO:SENIOR PAT TIME LECTURER INE OF PRESENTATION 1.Epidemiologic measures of association 2.Study.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
EBD for Dental Staff Seminar 2: Core Critical Appraisal Dominic Hurst evidenced.qm.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Modern Management of Cholesterol in the High-Risk Patient.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
Probability and odds Suppose we a frequency distribution for the variable “TB status” The probability of an individual having TB is frequencyRelative.
Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.
Date of download: 9/19/2016 From: Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem Ann.
NICE –CG 181 Continuum of CVD Risk and its treatment
The Anglo Scandinavian Cardiac Outcomes Trial
V. Atella, A. Brady, A. L. Catapano, J. Critchley, I. M. Graham, F. D
Volume 388, Issue 10059, Pages (November 2016)
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Classification of total cholesterol levels
FATS- Familial Atherosclerosis Treatment Study
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Teaching Tool: Blood Pressure Classification
Systolic Blood Pressure Intervention Trial (SPRINT)
The percentage of subjects with de novo development of renal function impairment (GFR
Volume 388, Issue 10059, Pages (November 2016)
Baseline characteristics of HPS participants by prior diabetes
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Section 9: Continuum of care: Summary and timeline
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Potential mechanisms whereby statins may reduce the risk of stroke
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
LDL - How low can you go? Terry Jacobsen, MD
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Characteristics of included studies
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Presentation transcript:

Biases in identifying risk factor thresholds: A new look at the "lower- is-better" controversy for cholesterol, blood pressure and other risk factors Ian Marschner Pfizer Australia & NHMRC Clinical Trials Centre

Linear Relationship Relationship between a risk factor and the occurrence of a disease event is essentially linear on an appropriate scale (usually the log-incidence scale) Existence of a linear relationship suggests a “lower-is-better” approach to risk factor modification

Example – Coronary and Vascular events related to cholesterol and blood pressure Law & Wald. BMJ Mortality per 1000 per year Relative Risk

Threshold Relationship Threshold: point at which a predominantly linear relationship between a risk factor and a disease event becomes effectively constant Existence of a threshold relationship can suggest less aggressive risk factor modification strategies since modification is of no benefit beyond a certain point

Example – CARE Trial LDL Cholesterol level (mg/dL) Relative risk (log scale) of recurrent coronary event

J-Curve Relationship J-curve: predominantly linear positive relationship between a risk factor and a disease event reverses and becomes negative Existence of a J-curve relationship can suggest less aggressive risk factor modification strategies since modification is of no benefit and may even be harmful beyond a certain point

Example – Framingham Study Note: J-curves have also been observed for stroke events

Randomised Studies Randomised studies of intensive versus moderate lowering of cholesterol support lower-is-better e.g. PROVE-IT study:

Example – CARE Trial LDL Cholesterol level (mg/dL) Relative risk (log scale) of recurrent coronary event

Randomised Studies Randomised studies of intensive versus moderate lowering of cholesterol support lower-is-better e.g. PROVE-IT study:

Conflicting Evidence Existence of conflicting evidence has complicated the assessment of whether lower-is-better for cholesterol and blood pressure One explanation for this is that bias has led to spurious non-linear threshold or J-curve relationships in some studies, particularly those on primary or secondary prevention cohorts

Explanation for conflicting evidence Confounding of primary risk factor and residual risk level in primary or secondary prevention studies –E.g. cholesterol level confounded with non-cholesterol risk level Effect modification often exists between primary risk factor and residual risk level –E.g. risk coronary event increases more quickly with cholesterol when the individual has lower non- cholesterol risk level Combined effect of confounding and effect modification is a spurious non-linear relationship even when the underlying relationship is a linear lower-is-better one

Plan for rest of talk 1.Provide evidence that there is confounding in primary and secondary prevention studies 2.Provide evidence that effect modification can exist, particularly in cardiovascular contexts 3.Explain how the two can combine to produce spurious non-linear relationships that could explain the apparent threshold and J-curve relationships seen in some prior studies

Confounding In patients selected because they have had a previous event (secondary prevention) or because they have not had a previous event (primary prevention) the risk factor and the residual risk level is confounded Example 1: In order to have had a prior heart attack, patients with low cholesterol have more non-cholesterol risk factors Example 2: In order not to have had a prior heart attack, patient with high cholesterol have less non- cholesterol risk factors

Example – Simulation Results Assumptions for simulated population: Incidence of coronary event is related to 8 risk factors (incl. cholesterol) according to a model No relationship between cholesterol and no. of non-cholesterol risk factors in the full population Coronary events simulated according to the risk factor model Primary and secondary prevention sub-populations identified

Example – LIPID Trial

Effect Modification Effect Modification: Event rate increases less quickly as the risk factor increases in patients with higher residual risk Examples: Coronary and vascular event rate increases less quickly with cholesterol level and blood pressure in patients with higher non-cholesterol and non-BP risk level

Examples LIPID: Rate ratio of coronary event for each unit of cholesterol Law: Rate ratio of coronary event for each unit of cholesterol PSC: Rate ratio of vascular event for each unit of blood pressure

Combination of Confounding and Effect Modification Confounding alone leads to linear attenuation of the risk factor relationship –Strength of association between risk factor and disease event may be under-estimated Combination of confounding and effect modification leads to non-linear attenuation –Association may appear to be threshold or J-curve

Linear Attenuation (confounding only) Risk level: P = primary risk factor R = residual risk level Incidence rate: log t;P,R) = log   t) + aP + bR Confounding: R = c + dP(d<0) Apparent relationship: log t;S) = log    t) + (a+bd)P Attenuation: a > a+bd

Hypothetical Effect Non cholesterol risk level

Non – linear attenuation (confounding and effect modification) Risk level: P = primary risk factor R = residual risk level Incidence rate: log t;S,NS) = log   t) + (a+a 0 R)P + bR Confounding: R = c + dP (d<0) Apparent relationship: log t;S) = log    t) + (a+a 0 c+bd)P + a 0 dP 2 Attenuation: apparent quadratic relationship

Hypothetical Effect Non cholesterol risk level

Theoretical Calculations (under the assumption that lower-is-better)

Apparent Relationships Bias can lead to apparent thresholds and J-curves even when the underlying model is linear

Adjustment for measurement error (regression dilution) Measurement error accounts for some but not all of the attenuation

Conclusions Analyses showing an apparent threshold relationship may not be inconsistent with a linear “lower is better” relationship Aggressive treatment strategies may be warranted despite an apparent threshold or J-curve in the risk factor Analyses adjusting for residual risk level are crucial and may ameliorate the bias

Randomised Studies Intervention strategies are best based on randomised trials comparing (less aggressive) threshold-based intervention with (more aggressive) non-threshold-based intervention Example: Despite earlier suggestions of a cholesterol threshold, large scale trials have now confirmed aggressive treatment of high risk patients even at lower cholesterol levels

Final Word Even when we are confident that there is no bias in the risk factor model, assessment of risk factor intervention strategies can be dangerous based solely on risk factor models derived from prospective cohort studies Degree of improvement in the risk factor may not be a complete “surrogate” for the effect of the intervention Randomised studies capture the complete effects of the intervention and are therefore preferable for assessing risk factor interventions strategies

Randomised Studies Intervention strategies are best based on randomised trials comparing (less aggressive) threshold-based intervention with (more aggressive) non-threshold-based intervention Example: Despite earlier suggestions of a cholesterol threshold, large scale trials have now confirmed aggressive treatment of high risk patients even at lower cholesterol levels

Example – Simulation Results Assumptions for simulated population: Incidence of coronary event is related to 8 risk factors (incl. cholesterol) according to a model No relationship between cholesterol and no. of non-cholesterol risk factors in the full population Coronary events simulated according to the risk factor model Primary and secondary prevention sub-populations identified